Diversified Consumer Services
Company Overview of Vanderbilt University
Vanderbilt University is an educational institution, which offers undergraduates, graduate, and professional programs in fields such as liberal arts and sciences, engineering, music, education, and human development. The schools of the university include Blair School of Music, College of Arts and Science, Divinity School, Graduate School, Law School, Owen Graduate School of Management, Peabody College, School of Engineering, School of Medicine, and School of Nursing. Vanderbilt University was established in 1873 and is based in Nashville, Tennessee. The university has endowment assets worth $2453.9 millions.
211 Kirkland Hall
Nashville, TN 37240
Founded in 1873
Key Executives for Vanderbilt University
Vice Chancellor and Chief Financial Officer
Associate Vice Chancellor and Chief Human Resource Officer
Vice Chancellor for Public Affairs
Vice Chancellor of Health Affairs
Compensation as of Fiscal Year 2012.
Vanderbilt University Key Developments
Vanderbilt University Names John M. Lutz as Vice Chancellor for Information Technology
Apr 15 13
Vanderbilt University has named John M. Lutz its first vice chancellor for information technology. Lutz, who most recently served as president of IBM Canada, will oversee all information technology at the university and medical center with the exception of clinical applications and IT funded by sponsored research. He is a member of the board of directors of the Conference Board of Canada, the Council of Canadian Chief Executives, and the advisory board of the Center for Talented Youth at Johns Hopkins University.
Vanderbilt University Wins $9.31 Million Federal Contract
Mar 28 13
Vanderbilt University won a $9,313,642 federal contract from the Defense Advanced Research Projects Agency, Arlington, Va., for META tools extension and maturation to support component-based design of complex cyberphysical systems.
Acorda Therapeutics, Inc. and Vanderbilt University Medical Center Announces Phase 1 Clinical Trial of Glial Growth Factor 2
Mar 7 13
Acorda Therapeutics, Inc. and collaborator Vanderbilt University Medical Center announced data from a Phase 1 clinical trial of Glial Growth Factor 2 (GGF2) designed to study safety, tolerability and exploratory measures of efficacy in people with heart failure who were already on optimized regimens of currently available therapies. The study evaluated the effects of a range of doses, with each participant receiving a single dose. Data from this trial, which enrolled patients at Vanderbilt and St. Joseph’s Hospital in Atlanta, GA, are being presented on Sunday, March 10 at the American College of Cardiology 62nd Annual Scientific Session in San Francisco, CA. In this study, a single dose of GGF2 in patients with heart failure was generally well tolerated up to 0.75 mg/kg. Among participants receiving GGF2, the most commonly observed adverse events were headache, site injection reaction and gastrointestinal symptoms. There were no notable effects of treatment on hematology or electrocardiogram, and no adverse events led to withdrawal from the study. A dose-limiting adverse event of hepatotoxicity (liver injury) meeting Hy’s Law criteria (elevated ALT, AST and bilirubin) occurred in the highest-dose cohort. The patient’s liver function tests and bilirubin had returned to normal by two weeks after dosing. There was also one reported case of uroepithelial carcinoma, a form of cancer in the cells that line the bladder, which was diagnosed three months after dosing in the highest-dose cohort. The patient’s baseline urinalysis showed the presence of red blood cells, indicating that the tumor was likely present prior to dosing. Ejection fraction findings: A left ventricle ejection fraction of 55% or higher is considered normal; all participants in the Phase 1 GGF2 trial had left ventricle ejection fraction of less than 40%. Trial participants receiving GGF2 showed a consistent and dose-responsive trend towards improving left ventricular ejection fraction over 28 and 90 days compared to placebo. Mean ejection fractions at screening in the treatment and placebo groups were 27% and 29%, respectively. For the cohort receiving the maximally tolerated dose (0.75 mg/kg) of GGF2, the mean ejection fraction at screening was 28% and the absolute mean changes in ejection fraction at day 8, day 14, day 28, and day 90 were 5%, 12%, 12.0% and 9.0%, compared to absolute mean changes of -1%, -1%, 0% and 2% for the placebo group; thus, the mean ejection fraction for this GGF2 group at day 28 was 40%, versus 29% for placebo. Acorda has discussed the findings from this initial study with the U.S. Food and Drug Administration (FDA) and has reached agreement on the next clinical study of GGF2 in heart failure. This study will primarily investigate further the safety profile of GGF2 across a range of doses, and will continue to explore efficacy outcomes. The FDA has granted Fast Track designation for GGF2 for the treatment of heart failure.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|